Evidence map›Paper›PMID 34426440›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2022

Establishment of Patient-Derived Succinate Dehydrogenase-Deficient Gastrointestinal Stromal Tumor Models for Predicting Therapeutic Response.

Mayra Yebra, Shruti Bhargava, Avi Kumar, Adam M Burgoyne, Chih-Min Tang, Hyunho Yoon, Sudeep Banerjee, Joseph Aguilera, Thekla Cordes, Vipul Sheth and 12 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 2 pooled it
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. SEOM-GEIS clinical guideline for gastrointestinal stromal tumors (2022).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023
    Guideline
  3. Trial
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. A Phase I, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Patients with Advanced Gastrointestinal Stromal Tumor.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023
    Article
  17. Review
  18. Current status of and future prospects for the treatment of unresectable or metastatic gastrointestinal stromal tumours.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2023
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors at 5 institutions in 2 countries.

Mayra Yebra *Moores Cancer Center, University of California San Diego, La Jolla, California.
Shruti Bhargava *Moores Cancer Center, University of California San Diego, La Jolla, California.
Avi KumarMoores Cancer Center, University of California San Diego, La Jolla, California.
Adam M BurgoyneMoores Cancer Center, University of California San Diego, La Jolla, California.ORCID 0000-0002-4351-9940
Chih-Min TangMoores Cancer Center, University of California San Diego, La Jolla, California.
Hyunho YoonMoores Cancer Center, University of California San Diego, La Jolla, California.
Sudeep BanerjeeMoores Cancer Center, University of California San Diego, La Jolla, California.
Joseph AguileraMoores Cancer Center, University of California San Diego, La Jolla, California.
Thekla CordesMoores Cancer Center, University of California San Diego, La Jolla, California.
Vipul ShethDepartment of Radiology, Stanford University, Palo Alto, Stanford, California.ORCID 0000-0001-6130-4276
Sangkyu NohMoores Cancer Center, University of California San Diego, La Jolla, California.
Rowan UstoyMoores Cancer Center, University of California San Diego, La Jolla, California.
Sam LiMoores Cancer Center, University of California San Diego, La Jolla, California.
Sunil J AdvaniMoores Cancer Center, University of California San Diego, La Jolla, California.
Christopher L CorlessDepartment of Pathology, OHSU Knight Cancer Institute, Portland, Oregon.
Michael C HeinrichHematology/Medical Oncology, Portland VA Health Care System and OHSU Knight Cancer Institute, Portland, Oregon.ORCID 0000-0003-3790-0478
Razelle KurzrockMoores Cancer Center, University of California San Diego, La Jolla, California.ORCID 0000-0003-4110-1214
Scott M LippmanMoores Cancer Center, University of California San Diego, La Jolla, California.
Paul T FantaMoores Cancer Center, University of California San Diego, La Jolla, California.
Olivier HarismendyMoores Cancer Center, University of California San Diego, La Jolla, California.ORCID 0000-0002-8098-9888
Christian MetalloMoores Cancer Center, University of California San Diego, La Jolla, California.
Jason K SicklickMoores Cancer Center, University of California San Diego, La Jolla, California. jsicklick@health.ucsd.edu.
University of San Diego · USUniversity of California San Diego · USOregon Health & Science University · USPalo Alto University · USPortland VA Medical Center · US

Funding

VIRAL MALIGNANCYP30CA023100 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Jesse Nodora · 1985 to 2026
$124.9M
Elucidation and therapeutic exploitation of PAK mediated radioresistanceR37CA215081 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ADVANI, SUNIL J · 2018 to 2024
$2.5M
Targeting Drug-Resistant Cancer Stem Cell Niches of Gastrointestinal Stromal TumorR01CA226803 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SICKLICK, JASON KEITH · 2019 to 2023
$2.1M
Non-essential amino acids and sphingolipid diversity in cancer progressionR01CA234245 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI METALLO, CHRISTIAN MICHAEL · 2019 to 2023
$1.9M
Exploiting Metabloic Defects in Tumors with Mutant IDH1 and IDH2R01CA188652 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI METALLO, CHRISTIAN MICHAEL · 2014 to 2018
$1.6M
Investigation of DNA Damaging Agents in GIST with Metabolic DysfunctionR01FD006334 · FDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SICKLICK, JASON KEITH · 2019 to 2021
$1.5M
FDA HHS R01 FD006334NCI NIH HHS P30 CA023100NCI NIH HHS R01 CA188652NCI NIH HHS R01 CA226803NCI NIH HHS R01 CA234245NCI NIH HHS R37 CA215081
6 · The paper itself

Abstract

purposeGastrointestinal stromal tumor (GIST) is the most common sarcoma of the gastrointestinal tract, with mutant succinate dehydrogenase ( EXPERIMENTAL

designWe describe methods for establishing novel patient-derived

resultsMolecular and metabolic characterization of our patient-derived m

conclusionsWe report the first methods to establish patient-derived m

Indexed as

Gastrointestinal NeoplasmsGastrointestinal Stromal TumorsAdolescentHumansMutationProto-Oncogene Proteins c-kitReceptor, Platelet-Derived Growth Factor alphaSuccinate DehydrogenaseYoung AdultProto-Oncogene Proteins c-kitReceptor, Platelet-Derived Growth Factor alphaSuccinate Dehydrogenase

Identifiers

PMID34426440
PMCPMC8738129
OpenAlexW3193537697

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.